Introduction

Co-founders of a biotech company in Seattle discuss their platform that utilizes synthetic biology and machine learning to evaluate protein-protein interactions at scale, aiding in the identification of drug candidates. The company's partnerships with major pharmaceutical companies highlight the potential of their technology in therapeutic projects.